A randomised phase III study of trastuzumab-docetaxel vs trastuzumab-vinorelbine as 1. line therapy for patients with metastatic HER2 positive breast cancer

Trial Profile

A randomised phase III study of trastuzumab-docetaxel vs trastuzumab-vinorelbine as 1. line therapy for patients with metastatic HER2 positive breast cancer

Completed
Phase of Trial: Phase III

Latest Information Update: 27 Feb 2017

At a glance

  • Drugs Docetaxel (Primary) ; Trastuzumab (Primary) ; Vinorelbine (Primary)
  • Indications Advanced breast cancer
  • Focus Therapeutic Use
  • Acronyms HERNATA
  • Most Recent Events

    • 29 May 2015 Results of P95HER2 as a predictive marker of trastuzumab resistance were presented at the 51st Annual Meeting of the American Society of Clinical Oncology.
    • 17 Dec 2010 Results published in Journal of Clinical Oncology.
    • 17 Dec 2010 Status changed from active, no longer recruiting to completed.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top